Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183602 | 0.98 | MAPK1 (0.50) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL10183038 | 0.94 | AR (0.44) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL26080794 | 0.78 | MAPK1 (0.40) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL25915799 | 0.76 | MAPK1 (0.43) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL3952325 | 0.75 | MAPK1 (0.56) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL23107314 | 0.73 | MAPK1 (0.58) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL16938257 | 0.73 | MAPK1 (0.58) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL25772014 | 0.73 | MAPK1 (0.58) | MAPK1HPGDLMNAHTTALDH1A1 | |
| SCHEMBL10183120 | 0.73 | WNT1 (0.34) | — | |
| SCHEMBL3549518 | 0.72 | HPGD (0.50) | MAPK1HPGDLMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-13 | — | — | US | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | MAPK1 3393/4885HPGD 178/4885LMNA 579/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4069/4885HPGD 1080/4885LMNA 1845/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MAPK1 3643/4885HPGD 2520/4885LMNA 1606/4885 |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK1 273/4885HPGD 2536/4885LMNA 3593/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885HPGD 1749/4885LMNA 1308/4885 |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | MAPK1 305/4885HPGD 4253/4885LMNA 1729/4885 |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | MAPK1 305/4885HPGD 4253/4885LMNA 1729/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4069/4885HPGD 1080/4885LMNA 1845/4885 |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, OPRK1 | MAPK1 3393/4885HPGD 178/4885LMNA 579/4885 |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | MAPK1 3431/4885HPGD 2198/4885LMNA 938/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | MAPK1 3431/4885HPGD 2198/4885LMNA 938/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885HPGD 1749/4885LMNA 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.